Navigation Links
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
Date:7/2/2009

CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers. The principal investigators for the trial are Dr. Kevin Harrington of The Institute of Cancer Research, London, England, and Dr. Geoff Hall of St. James's Institute of Oncology, Leeds.

A total of 30 patients have been treated in the Phase I/II trial (REO 011), including 23 head and neck cancer patients. Of these head and neck patients, 17 patients have been treated in the Phase II portion of the trial.

Eligible patients in the Phase II portion of the trial included those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists.

Interim results reported in March 2009 demonstrated that of 12 head and neck patients evaluable for clinical response, five had experienced a partial response (PR) and four had experienced stable disease (SD) ranging from two to six months, for a clinical benefit rate of 75%.

"This is an outstanding response rate in this difficult-to-treat patient population, and formed the basis of the Phase III pivotal program now being developed for REOLYSIN in combination with carboplatin/paclitaxel for head and neck cancer patients," said Dr. Brad Thompson, President and CEO of Oncolytics.

Final results of the trial are expected to be released later this year.

An independent, confirmatory Phase II trial using the same combination of REOLYSIN and carboplatin/paclitaxel for patients with head and neck cancers is currently underway in the U.S.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase I/II REOLYSIN paclitaxel and carboplatin trial and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
2. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
3. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
4. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
5. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
7. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
8. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
9. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
10. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
11. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... bring to market a pioneering medical device for the treatment of Age-Related Macular ... contract with Emergo, a global regulatory consultancy that helps companies like ours secure ...
(Date:1/21/2017)... 20, 2017 Bioptix, Inc. (Nasdaq: ... that on January 14, 2017 the Board of Directors ... Company will terminate certain employees associated with the September ... Company commenced terminations on January 16, 2017 and terminations ... Company may pay severance benefits in certain circumstances of ...
(Date:1/21/2017)... Mass. , Jan. 21, 2017   Boston ... novel compounds designed to target cancer stemness pathways, today ... investigational compound, napabucasin, at the 2017 American Society of ... San Francisco . In a ... investigational agent designed to inhibit cancer stemness pathways by ...
(Date:1/20/2017)... 2017 Stock-Callers.com explores the Biotech ... the most recent performances of select equities. In this ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ABEO ... and Sage Therapeutics Inc. (NASDAQ: SAGE ). ... Research, global Biotech market size is expected to reach $604.40 billion by 2020 ...
Breaking Biology Technology:
(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
(Date:1/6/2017)...  SomaLogic announced today that it has agreed ... iCarbonX, the China -based company ... Health Ecosystem that can define each person,s ,digital ... behavioral and psychological data, the Internet and artificial ... will provide proteomics data and applications expertise to ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):